BASF Pion 11/8/22 Webinar | Enabling SEDDS Formulation Choice Through In Vitro-In Vivo Correlation

- Recorded webinar -
"Enabling self-emulsifying drug delivery systems (SEDDS) Formulation Choice through In Vitro-In Vivo Correlation for high throughput screening of SEDDS formulations in vitro to predict in vivo ranking."

SEDDS formulations consist of complex mixtures of lipid-surfactant agents in order to match the target interfacial tension.

The absorption rate of the Active Pharmaceutical Ingredient (API) can be enhanced by fine tuning the composition of SEDDS.

In this webinar, you can learn the steps BASF took, in partnership with Pion, in developing enhanced SEDDS formulations based on their surfactant emulsion properties, including droplet size and hydrophilicity. BASF generated in vitro information via Pion technology, and as a result, were able to report enhanced IVIVC performance for SEDDS formulations.

Speakers:

Nitin K Swarnakar, NA Applications Manager @BASF Pharma Solutions Dr. Swarnakar has 15 years of combined academic and industrial experience, 11 Indian and 4 US Patents (application/granted), plus more than 30 publications. He has a Bachelor and Masters degrees in Pharma as well as a Doctorate of Philosophy (Pharmaceutics). His key formulation specialties are solubilization of small molecules and peptides, in vitro-in vivo correlation, lipid based formulations and polymer based formulations.

Karl Box, Chief Scientific Officer Europe, Pion Inc, Karl Box is Chief Scientific Officer (Europe) at Pion Inc. and is involved in scientific and chemistry-related functions within the company, as well as supporting commercial activities and business development. His expertise is in the field of physicochemical measurements where he has forged a successful career in the development of new instrumentation and assays for supporting drug discovery and development.

THANK YOU to our fine partners at BASF Pharma Solutions

Pion Inc. Bridging the gap between in vitro experiments and in vivo outcomes